



Aria Neurosciences, Inc.

PRESS RELEASE

Aria Announces Promising Results with Alzheimer's Compound

Hamden, CT (USA) June 9. Aria Neurosciences, Inc. (www.arianeurosciences.com) announced that a team led by Martin Sadowski, MD, PhD, associate professor of neurology, psychiatry, and biochemistry and molecular pharmacology at NYU Langone Medical Center, published preclinical results for its compound ARN-2966 (2-PMAP). The work appeared online in *Annals of Neurology* on June 03 (*Asuni AA et al. Ann Neurol (2014) DOI:10.1002/ana.24149*). Aria is an emerging biopharmaceutical company dedicated to developing and commercializing novel disease modifying therapies for Alzheimer's disease (AD).

Dr. Sadowski's laboratory conducted cell and transgenic mouse studies with 2-PMAP, part of Aria Neurosciences' library of compounds. The new study describes the biological properties of this compound. The research revealed that 2-PMAP reduced the production of amyloid beta's mother protein, known as amyloid precursor protein (APP), and also had the same impact on amyloid proteins in the brains of transgenic mice used as animal models of AD. Importantly 2-PMAP also prevented the cognitive deficits that are normally seen in these mice as they age. The studies also suggest that the compound appears to have a highly selective effect, by interfering with the translation of APP's gene transcript into the APP protein itself.

Aria and NYU are co-inventors of ARN compounds, and Aria holds the exclusive license from NYU. According to Aria's CEO, Dr. Bijan Almassian "We are very pleased with the preclinical results seen with 2-PMAP. Our initial round of financing will enable us to optimize further our lead development candidate for investigational new drug [IND] enabling studies."

Aria NeuroSciences, Inc
295 Washington Ave, Suite 4N
Hamden, CT 06518

Tel: 203-230-8596

Website: www.arianeurosciences.com

Alzheimer's disease, the most common form of dementia, currently afflicts more than five million Americans, according to the Alzheimer's Association. Unless preventive drugs or treatments are developed, the prevalence of Alzheimer's is expected to triple by 2050.

**For further information please contact:
Aria Neurosciences, Inc.**

Dr. Bijan Almassian
Chairman
295 Washington Ave, Suite 4N
Hamden, CT 06518
Tel: 203-230-8596
Email: balmassian@arianeurosciences.com